N,N'-diisopropylglycinamide | 97454-48-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N'-diisopropylglycinamide
• 英文别名: N-(1-Methylethyl)-2-[(1-methylethyl)amino]acetamide；N-propan-2-yl-2-(propan-2-ylamino)acetamide
• CAS: 97454-48-3
• 化学式: C₈H₁₈N₂O
• mdl: MFCD09806182
• 分子量: 158.244
• InChiKey: FKFMOXQPSHWSFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N'-diisopropylglycinamide 在 sodium hydroxide 、 三乙胺 作用下， 以 氯乙酰氯 、 甲苯 为溶剂， 以94.4%的产率得到1,4-di-isopropylpiperazine-2,5-dione
  参考文献：
  名称：

  US4694081

  摘要：

  公开号：

文献信息

• Compounds Useful as Antagonists of CCR2
  申请人：Sprott Kevin

  公开号：US20100016289A1

  公开（公告）日：2010-01-21

  The present invention provides compounds of general formula I: (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R 1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR 2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供一般式I的化合物：（I）或其药学上可接受的盐，其中X、n、Y和R1在此通常和子集中定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、紊乱或状况。
• Process to prepare 2,5-diketopiperazines
  申请人：Monsanto Company

  公开号：EP0216746A2

  公开（公告）日：1987-04-01

  Substituted and unsubstituted 2,5-diketo­piperazines can be prepared by a process which comprises bringing together a substituted or unsubstituted glycin­amide and a haloacetyl halide, optionally in the pre­sence of a non-nucleophilic base, and thereafter adding a stronger base.

  取代和未取代的 2,5-二酮哌嗪可以通过以下方法制备：将取代或未取代的甘氨酰胺 和卤乙酰卤（可选择在有非亲核碱存在的情况下）混合在一起，然后加入更强的碱。
• The compound 1,4-diisopropyl-2,5-diketopiperazine
  申请人：Monsanto Company

  公开号：EP0216744B1

  公开（公告）日：1991-08-14
• MILLER, WILLIAM H.;TAYLOR, WILLIAM D.
  作者：MILLER, WILLIAM H.、TAYLOR, WILLIAM D.

  DOI：——

  日期：——
• ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL
  申请人：Tsai Li-Huei

  公开号：US20100075926A1

  公开（公告）日：2010-03-25

  The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.